FDA Panel: All Thumbs Down for GLP-1 Agonist Implant for Diabetes
MedPageToday - September 22, 2023
Jill Crandall, M.D., a member of the FDA's Endocrinologic and Metabolic Drugs Advisory Committee, explains that she voted against approving an implant device for type 2 diabetes in part because patient data weren't consistent regarding the device's delivery of a GLP-1 agonist drug. Dr. Crandall is professor of medicine and the Jacob A. and Jeanne E. Barkey Chair in Medicine at Einstein, and chief of endocrinology at Einstein and Montefiore.
Rich People Are Hogging Ozempic, Making the Drug Harder to Access for People With Diabetes
Salon - March 06, 2023
Jill Crandall, M.D., says shortages of the diabetes drug Ozempic, which is widely used for weight-loss, have forced physicians to prescribe alternative medications, resulting in higher costs, new and different side effects, and increased blood sugar monitoring requirements for patients. Dr. Crandall is professor of medicine and the Jacob A. and Jeanne E. Barkey Chair in Medicine at Einstein, and chief of endocrinology at Einstein and Montefiore.
Do Statins Increase the Risk of Diabetes?
The New York Times - October 25, 2022
Jill Crandall, M.D., discusses the link between statins and diabetes risk, noting that the risk is modest, but higher, for those who are prediabetic when they begin taking statins to lower their blood cholesterol levels. Dr. Crandall is professor of medicine and the Jacob A. and Jeanne E. Barkey Chair in Medicine at Einstein, and chief of endocrinology at Einstein and Montefiore.
Forbes interviews Jill Crandall, M.D., about resveratrol, an extract of red wine, and its potential to boost metabolism in humans. Dr. Crandall, who studies resveratrol’s effect on insulin sensitivity, notes that the research in humans is still too early and does not provide enough evidence to suggest that people take supplements. Dr. Crandall is associate professor of clinical medicine at Einstein and attending physician of endocrinology at Montefiore Medical Center.
June 25, 2013
MSN features Jill Crandall, M.D., in an article that dispels some current myths about insulin therapy. Dr. Crandall notes that insulin injections can be a lifesaving therapy for both type 1 and type 2 diabetics, who cannot control the disease with diet and exercise alone, and discusses the changes in insulin delivery methods, including finer needles and injector pens, that are making insulin dosage more convenient and less painful than ever before. Dr. Crandall is associate professor of clinical medicine.
November 3, 2010
U.S. News & World Report (via Science News) features Jill Crandall, M.D., and her pilot study, which indicates that resveratrol, the substance widely known to be found in red wine and thought to impart health benefits, improves insulin resistance. Dr. Crandall emphasized that while the results of her small study were promising, they are preliminary and the benefits of resveratrol remain unproven. Dr. Crandall is associate professor of clinical medicine.
More coverage on this story
Orlando Sentinel
MedPage Today
DiabetesHealth
June 29, 2010
Asian News International (ANI) features research by Jill Crandall, M.D., regarding her study linking diabetes and heart disease published in the online editon of the Journal of Clinical Endocrinology & Metabolism. The study focuses on cardiovascular risk profile of older adults with pre-diabetes. Dr. Crandall is associate professor of clinical medicine.
More coverage on this story
The Times of India
March 4, 2009